You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma
|
|---|---|
| Published in |
BMC Nephrology, September 2014
|
| DOI | 10.1186/1471-2369-15-156 |
| Pubmed ID | |
| Authors |
Liliane Hobeika, Sally E Self, Juan Carlos Q Velez |
| Abstract |
Proteasome inhibitors are a relatively new class of chemotherapeutic agents. Bortezomib is the first agent of this class and is currently being used for the treatment of multiple myeloma. However, recent reports have linked exposure to bortezomib with the development of thrombotic microangiopathy. A new agent in this class, carfilzomib, has been recently introduced as alternative therapy for relapsing and refractory multiple myeloma. We report a case of renal thrombotic microangiopathy associated with the use of carfilzomib in a patient with refractory multiple myeloma. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 2% |
| Unknown | 59 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 17% |
| Researcher | 9 | 15% |
| Student > Doctoral Student | 7 | 12% |
| Other | 7 | 12% |
| Student > Postgraduate | 5 | 8% |
| Other | 9 | 15% |
| Unknown | 13 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 42% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 13% |
| Nursing and Health Professions | 3 | 5% |
| Agricultural and Biological Sciences | 3 | 5% |
| Computer Science | 2 | 3% |
| Other | 6 | 10% |
| Unknown | 13 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 January 2020.
All research outputs
#15,306,466
of 22,764,165 outputs
Outputs from BMC Nephrology
#1,441
of 2,463 outputs
Outputs of similar age
#146,728
of 252,706 outputs
Outputs of similar age from BMC Nephrology
#22
of 43 outputs
Altmetric has tracked 22,764,165 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,463 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 252,706 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.